Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

SpringWorks Therapeutics (SWTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ...

We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

Whales with a lot of money to spend have taken a noticeably bullish stance on SpringWorks Therapeutics. If we consider the ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of ...